findmyKOL

Jeffrey Rade, MD

Basic profile

UMass Memorial Health Care

ORCIDNPI
RegionWorcester, MA · NortheastSpecialtyInterventional CardiologyFocusCardiology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPaymentsNone reportedNIH funding2010–2026Why? →

Jeffrey Rade is a Cardiology physician affiliated with UMass Memorial Health Care. OpenAlex indexes 94 publications with 8,006 citations (h-index 29); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Interventional Cardiology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
94publications

Distinct works indexed by OpenAlex, matched via ORCID.

8,006citations

Total citations across indexed works.

29h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
2NIH grants · 2010–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

55 Lake Ave N
Worcester, MA 016550002

Telephone

508-334-3452

Provider last certified this registry record 14 Nov 2020.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    88.9%
    Statin32.5%
    Rosuvastatin Calcium58%Atorvastatin Calcium38%Simvastatin4%
    Part D<11 patients
    Beta blocker16.1%
    Metoprolol Succinate62%Carvedilol24%Metoprolol Tartrate15%
    Part D<11 patients

    + 12 more classes in this area

  • Blood & clotting

    8.4%
    Factor Xa inhibitor5.8%
    Eliquis68%Xarelto32%
    Part D<11 patients
    P2Y12 inhibitor2.5%
    Clopidogrel100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    2.7%
    SGLT2 inhibitor1.5%
    Jardiance100%
    Part D<11 patients
    Potassium supplement1.2%
    Potassium Chloride100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 20102026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”